Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients

Yana Debie; Jonas R M Van Audenaerde; Timon Vandamme; Lieselot Croes; Laure-Anne Teuwen; Lise Verbruggen; Greetje Vanhoutte; Elly Marcq; Lisa Verheggen; Debbie Le Blon; Bart Peeters; Maria E Goossens; Pieter Pannus; Kevin K Ariën; Sébastien Anguille; Annelies Janssens; Hans Prenen; Evelien L J Smits; Christof Vulsteke; Eva Lion; Marc Peeters; Peter A van Dam

doi:10.1158/1078-0432.CCR-22-2185

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients

Yana Debie, Jonas R M Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E Goossens, Pieter Pannus, Kevin K Ariën, Sébastien Anguille, Annelies Janssens, Hans Prenen, Evelien L J Smits, Christof Vulsteke, Eva LionMarc Peeters, Peter A van Dam

Research output: Contribution to journal › A1: Web of Science-article › peer-review

9 Downloads (Pure)

Abstract

PURPOSE: Cancer patients display reduced humoral responses after double-dose COVID-19 vaccination while their cellular response is more comparable to that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and cancer patients. Due to the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in cancer patients.

EXPERIMENTAL DESIGN: 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARSCoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T cell responses against SARS-CoV-2 specific S1 and S2 peptides.

RESULTS: Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects (GMT 1755.90 BAU/mL [95% CI 1276.95-2414.48] vs 1495.82 BAU/mL (95% CI 1131.48-1977.46)). However, homologous boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels.

CONCLUSIONS: In cancer patients who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.

Original language	English
Journal	Clinical Cancer Research
Volume	29
Issue number	3
Pages (from-to)	635–646
Number of pages	12
ISSN	1078-0432
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-2185
Publication status	Published - 2022

Access to Document

10.1158/1078-0432.CCR-22-2185Licence: Unspecified

2022ccre0635Final published version, 5.09 MB

Cite this

Debie, Y., Van Audenaerde, J. R. M., Vandamme, T., Croes, L., Teuwen, L.-A., Verbruggen, L., Vanhoutte, G., Marcq, E., Verheggen, L., Le Blon, D., Peeters, B., Goossens, M. E., Pannus, P., Ariën, K. K., Anguille, S., Janssens, A., Prenen, H., Smits, E. L. J., Vulsteke, C., ... van Dam, P. A. (2022). Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients. Clinical Cancer Research, 29(3), 635–646. https://doi.org/10.1158/1078-0432.CCR-22-2185

@article{16f36d009b334eedb39468b2ebffb569,

title = "Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients",

abstract = "PURPOSE: Cancer patients display reduced humoral responses after double-dose COVID-19 vaccination while their cellular response is more comparable to that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and cancer patients. Due to the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in cancer patients.EXPERIMENTAL DESIGN: 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARSCoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T cell responses against SARS-CoV-2 specific S1 and S2 peptides.RESULTS: Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects (GMT 1755.90 BAU/mL [95% CI 1276.95-2414.48] vs 1495.82 BAU/mL (95% CI 1131.48-1977.46)). However, homologous boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels.CONCLUSIONS: In cancer patients who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.",

author = "Yana Debie and {Van Audenaerde}, {Jonas R M} and Timon Vandamme and Lieselot Croes and Laure-Anne Teuwen and Lise Verbruggen and Greetje Vanhoutte and Elly Marcq and Lisa Verheggen and {Le Blon}, Debbie and Bart Peeters and Goossens, {Maria E} and Pieter Pannus and Ari{\"e}n, {Kevin K} and S{\'e}bastien Anguille and Annelies Janssens and Hans Prenen and Smits, {Evelien L J} and Christof Vulsteke and Eva Lion and Marc Peeters and {van Dam}, {Peter A}",

note = "FTX",

year = "2022",

doi = "10.1158/1078-0432.CCR-22-2185",

language = "English",

volume = "29",

pages = "635–646",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

Debie, Y, Van Audenaerde, JRM, Vandamme, T, Croes, L, Teuwen, L-A, Verbruggen, L, Vanhoutte, G, Marcq, E, Verheggen, L, Le Blon, D, Peeters, B, Goossens, ME, Pannus, P, Ariën, KK, Anguille, S, Janssens, A, Prenen, H, Smits, ELJ, Vulsteke, C, Lion, E, Peeters, M & van Dam, PA 2022, 'Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients', Clinical Cancer Research, vol. 29, no. 3, pp. 635–646. https://doi.org/10.1158/1078-0432.CCR-22-2185

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients. / Debie, Yana; Van Audenaerde, Jonas R M; Vandamme, Timon et al.
In: Clinical Cancer Research, Vol. 29, No. 3, 2022, p. 635–646.

Research output: Contribution to journal › A1: Web of Science-article › peer-review

TY - JOUR

T1 - Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients

AU - Debie, Yana

AU - Van Audenaerde, Jonas R M

AU - Vandamme, Timon

AU - Croes, Lieselot

AU - Teuwen, Laure-Anne

AU - Verbruggen, Lise

AU - Vanhoutte, Greetje

AU - Marcq, Elly

AU - Verheggen, Lisa

AU - Le Blon, Debbie

AU - Peeters, Bart

AU - Goossens, Maria E

AU - Pannus, Pieter

AU - Ariën, Kevin K

AU - Anguille, Sébastien

AU - Janssens, Annelies

AU - Prenen, Hans

AU - Smits, Evelien L J

AU - Vulsteke, Christof

AU - Lion, Eva

AU - Peeters, Marc

AU - van Dam, Peter A

N1 - FTX

PY - 2022

Y1 - 2022

N2 - PURPOSE: Cancer patients display reduced humoral responses after double-dose COVID-19 vaccination while their cellular response is more comparable to that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and cancer patients. Due to the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in cancer patients.EXPERIMENTAL DESIGN: 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARSCoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T cell responses against SARS-CoV-2 specific S1 and S2 peptides.RESULTS: Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects (GMT 1755.90 BAU/mL [95% CI 1276.95-2414.48] vs 1495.82 BAU/mL (95% CI 1131.48-1977.46)). However, homologous boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels.CONCLUSIONS: In cancer patients who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.

AB - PURPOSE: Cancer patients display reduced humoral responses after double-dose COVID-19 vaccination while their cellular response is more comparable to that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and cancer patients. Due to the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in cancer patients.EXPERIMENTAL DESIGN: 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARSCoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T cell responses against SARS-CoV-2 specific S1 and S2 peptides.RESULTS: Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects (GMT 1755.90 BAU/mL [95% CI 1276.95-2414.48] vs 1495.82 BAU/mL (95% CI 1131.48-1977.46)). However, homologous boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels.CONCLUSIONS: In cancer patients who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.

U2 - 10.1158/1078-0432.CCR-22-2185

DO - 10.1158/1078-0432.CCR-22-2185

M3 - A1: Web of Science-article

C2 - 36341493

SN - 1078-0432

VL - 29

SP - 635

EP - 646

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 3

ER -

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients

Abstract

Access to Document

Fingerprint

Cite this